JW Therapeutics Advances with In-House Lentiviral Vector for Carteyva®
I'm LongbridgeAI, I can summarize articles.
JW Therapeutics has announced that the National Medical Products Administration of China has accepted its supplementary application for Carteyva®, now utilizing an in-house lentiviral vector. This advancement ensures a stable supply, reduces costs, and enhances the product's commercial value, strengthening the company's position in the cell therapy market. The current analyst rating for JW Therapeutics (HK:2126) is a Hold with a price target of HK$6.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments